Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$372.71 2.85 (0.76)%
Market Cap 38.60B
12/02/16 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
2016 ACR Annual Meeting
Nov 16, 2016
25th Annual Credit Suisse Healthcare Conference
Nov 8, 2016 | 10:00 AM